Amneal Pharmaceuticals announces that the US FDA has approved CREXONT (carbidopa and levodopa) extended release capsules for the treatment of Parkinson’s disease. As an oral formulation of carbidopa/levodopa (CD/LD), the product combines immediate-release (IR) granules and extended-release (ER) pellets. Its therapeutic benefits include more “Good On” time with less frequent dosing; lasting efficacy as it is a formulation of IR granules with carbidopa and levodopa for rapid onset of action, and ER pellets with levodopa for long-lasting efficacy; and a safety profile consistent with IR CD/LD with the most common adverse reactions of nausea and anxiety.